Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of…
-Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to-moderate Alzheimer’s disease-
Category Archives: Global News Feed
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival,…
Basel, October 1, 2020 – Novartis Gene Therapies today announced new interim data from the ongoing Phase 3 STR1VE-EU clinical trial for Zolgensma® (onasemnogene abeparvovec) that demonstrated patients with spinal muscular atrophy (SMA) Type 1 continued to experience significant therapeutic benefit, including event-free survival, rapid and sustained improvement in motor function and motor milestone achievement, including for some patients with more aggressive disease at baseline compared to previous trials. SMA is a rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene that results in the progressive and irreversible loss of motor neurons, affecting muscle functions, including breathing, swallowing, and basic movement.1,2,3 These data as of December 31, 2019, and presented today during a virtual Clinical Trial Poster Session as part of the World Muscle Society (WMS) 2020 Virtual Congress, support the robust clinical evidence that has demonstrated a consistent, transformative benefit across Zolgensma clinical trials for the treatment of patients with SMA.
See the rest here:
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival,...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
Read more here:
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the company’s ongoing studies in patients with facioscapulohumeral muscular dystrophy (FSHD) during the 25th International Congress of the World Muscle Society.
Go here to read the rest:
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
The Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration
Translate Bio to Participate in Upcoming Investor Conferences
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:
Read the original here:
Translate Bio to Participate in Upcoming Investor Conferences
OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
SUWON, Republic of Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, presents two virtual posters of their on-going clinical research at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society on September 27 – 30. The presentations will focus on the results of the Company’s proprietary asymmetric siRNA (asiRNA) study, which confirms the therapeutic effects of RNAi-based therapeutics in patients with hepatic diseases and age-related macular degeneration.
Read the original post:
OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.
Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research
Continued here:
CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.
AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million
SAN JOSE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has entered into an agreement with Keystone Capital Partners (“Keystone”) for a preferred stock investment of US$7.0 Million. Additional details on the transaction are outlined in the accompanying Registration Statement filed on September 30, 2020 (File No. 333?249170).
Read the original here:
AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million
Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics
COPENHAGEN, Denmark, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies and vaccines, announces today that it has received DKK 4.8 million (approx. $800,000) in funding from Innovation Fund Denmark for the development of its new RAVEN platform, an integral part of Evaxion’s Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses (AICoV) program.
Continued here:
Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics